Combination of gemcitabine-containing magnetoliposome and oxaliplatin-containing magnetoliposome in breast cancer treatment: A possible mechanism with potential for clinical application
Metrics: PDF 1869 views | HTML 2170 views | ?
Hui Ye1, Jiansong Tong2, Jiangyi Liu3, Wenman Lin3, Chengshou Zhang3, Kai Chen4, Jie Zhao5, Wenjing Zhu4
1School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China
2Department of Cellular and Molecular Biology, The Scripps Research Institute, La Jolla, CA 92037, USA
3School of Ophthalmology and Optometry, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China
4School of Renji, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China
5School of the First Clinical Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, 325035, China
Hui Ye, email: email@example.com
Keywords: gemcitabine, oxaliplatin, magnetoliposome, breast cancer, MCF-7
Received: February 27, 2016 Accepted: May 09, 2016 Published: May 27, 2016
Breast cancer is a major global health problem with high incidence and case fatality rates. The use of magnetoliposomes has been suggested as an effective therapeutic approach because of their good specificity for cancers. In this study, we developed two novel magnetoliposomes, namely, Gemcitabine-containing magnetoliposome (GML) and Oxaliplatin-containing magnetoliposome (OML). These magnetoliposomes were combined (CGOML) was used to treat breast cancer under an external magnetic field. Biosafety test results showed that GML and OML were biologically safe to blood cells and did not adversely affect the behavior of mice. Pharmacokinetic and tissue distribution studies indicated that both magnetoliposomes exhibited stable structures and persisted at the target area under an external magnetic field. Cell and animal experiments revealed that CGOML can markedly suppress the growth of MCF-7 cells, and only the CGOML group can minimize the tumor size among all the groups. Finally, CGOML can significantly inhibit MCF-7cell growth both in vitro and vivo by activating the apoptotic signaling pathway of MCF-7 cells.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.